Overview

Pharmacokinetics/Pharmacodynamics of Argatroban Injection in End-Stage Renal Disease Patients Undergoing Hemodialysis

Status:
Completed
Trial end date:
2002-11-01
Target enrollment:
Participant gender:
Summary
The primary goals of this investigation are to provide guidance on how to dose Argatroban in patients undergoing hemodialysis and to assess the safety and tolerability of Argatroban in hemodialysis patients. The secondary goal of the study will be to assess the adequacy of anticoagulation during hemodialysis.
Phase:
Phase 4
Details
Lead Sponsor:
Texas Biotechnology Corporation
Treatments:
Argatroban